The Biotech Investor's Bible

The Biotech Investor's Bible

by George Wolff (Author)

Synopsis

A one-stop source for investing in biotech-with detailed coverage of the science, the business, the players, and the strategies for one of today's most promising (and volatile) industries To invest in biotech is to invest in the future, and as such, investors need to learn the nuances of the science they're putting their money on. The core asset of biotech companies is knowledge, and sound investment decisions are impossible without an understanding of this complex science. That's where The Biotech Investor's Bible fits in. This much-needed, one-of-a-kind resource simplifies the complex science surrounding the business of biotech and clarifies subtle distinctions within the context of their financial repercussions. The book explains the basics of genetics, patents, and therapies; and teaches investors how to value biotech companies and their state-of-the art products and technology. The Biotech Investor's Bible offers an informative summary of the relatively short history of the industry and provides a comprehensive review of various industry sectors. George Wolff (St. Pete Beach, FL) is a successful consultant advising clients who are investing in biotech stocks. He has assessed well over 150 biotech companies and has issued a number of valuable white papers that have charted the success of the hottest biotech companies.

$13.84

Save:$30.00 (68%)

Quantity

1 in stock

More Information

Format: Illustrated
Pages: 335
Edition: 1
Publisher: Wiley
Published: 29 Jun 2001

ISBN 10: 0471412791
ISBN 13: 9780471412793

Author Bio
GEORGE WOLFF is an award-winning journalist and, currently, a private business consultant to several firms in the investment industry. He has assessed and reported on more than 200 biotechnology companies for his clientele, issuing a number of valuable white papers charting the emergence of biotechnology. Previously, as a journalist, Wolff worked internationally covering the onset of the AIDS epidemic, the emergence of recombinant DNA technology, and the extraordinary stock market events of the previous twenty years. Wolff can be contacted through his web site, BioWolff.com.